September 15, 2010

ATTN:  Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re:  2010-11 Seasonal Trivalent Influenza Vaccine

The National Advisory Committee on Immunization (NACI) "Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011" has been published in the Canada Communicable Disease Report (CCDR) August 2010 Volume 36 ACS-6 and is available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-6/index-eng.php

The seasonal influenza vaccines to be marketed in Canada for the 2010 -11 season will contain: an A/California/7/2009(H1N1)-like virus, an A/Perth/16/2009(H3N2)-like virus, and a B/Brisbane/60/2008(Victoria lineage)-like virus.

A/California/7/2009(H1N1) was the recommended component for the monovalent pandemic H1N1 vaccine used in 2009 -10. The A/H3N2 virus has changed from the 2009-10 TIV formulation, while the B remains unchanged.
As in previous years, three TIV products will be supplied to British Columbia for this year’s public campaign. These include:

1. **FLUVIRAL®** (inactivated split virion product comprising the bulk of the publicly supplied influenza vaccine for British Columbia approved for people ≥6 months of age; distributed by GlaxoSmithKline Inc)
2. **VAXIGRIP®** (inactivated split virion thimerosal-reduced vaccine for people ≥6 months of age; distributed by Sanofi Pasteur Limited)
3. **INFLUVAC™** (inactivated split virion thimerosal-free vaccine for people ≥18 years of age; available in limited amounts for those who have a history of anaphylactic reaction to thimerosal and distributed by Solvay Pharma Inc).

In the event that redistribution of influenza vaccine is required, please keep the insulated shipping cartons in which your initial order was shipped. Health Authorities that find they have a surplus of vaccine should promptly notify BCCDC Biologicals Desk by fax (604-707-2581). The Biologicals Desk will advise regarding the management of any surplus vaccine.

In addition, three other trivalent influenza vaccine products have been approved for use in Canada. These products will not be offered through the publicly funded immunization campaign but may be available for private purchase. NACI statements for these products are pending. Any interim use of these products requires review of the product monographs or other suggested material provided in the placeholder of the Immunization Chapter:

1. **AGRIFLU®** (inactivated subunit thimerosal-free product for people ≥6 months of age; distributed by Novartis Vaccines and Diagnostics Inc.)
2. **FLUMIST®** (live attenuated product approved for people 2-59 years of age and administered as an intranasal spray; distributed by AstraZeneca Canada)
3. **INTANZA®** (inactivated split virion intradermal preparation for adults (18-59 years of age; 9 μg HA per strain) and seniors (≥ 60 years of age; 15 μg HA per strain); distributed by Sanofi Pasteur Limited). It is likely that only the 9 μg HA per strain adult version of this product will be available for the coming season.

**Last Season’s (2009-10) Vaccines**

Do not use formulations from the 2009 -10 season for the 2010-11 influenza vaccination campaign [i.e., adjuvanted pH1N1 (Arepanrix™), unadjuvanted Clinical Formulation pH1N1, monovalent pH1N1 vaccine (without adjuvant) or TIV]. Do not destroy any vaccines locally.
All influenza vaccine remaining from the previous year’s program should be returned to the BCCDC as soon as possible upon BCCDC authorization. Complete the Biologicals Return and Redistribution Requirements form available at [http://www.bccdc.ca/NR/rdonlyres/8E4A7D10-B3AE-48CA-8155-F09EF19B6FCC/0/FieldReturnFormJuly2010.xls](http://www.bccdc.ca/NR/rdonlyres/8E4A7D10-B3AE-48CA-8155-F09EF19B6FCC/0/FieldReturnFormJuly2010.xls) Contact the BCCDC Biologicals desk at 604-707-2582 for a return authorization number.

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

**Page 31, Seasonal trivalent influenza vaccine indications:**
- Separate phases used in 2009-10 season for elderly versus other recommended recipients have been removed.
- Adults who are morbidly obese (BMI ≥40) have been added to the list of recommended recipients under Group (1) “People at high risk”.
- Also added to Group (1) are Aboriginal peoples (on and off reserve) for the 2010 – 2011 season.
- Adults who are morbidly obese (BMI ≥40) and Aboriginal peoples have been added following recommendations from the Communicable Disease Policy Committee. These groups experienced higher rates of pH1N1-related hospitalization for and severe outcomes during the 2009 pandemic.
- Group (4) “Volunteers for the 2010 Winter Olympic Games including the Paralympic Games” has been removed.

**Pages 32 and 33, FLUVIRAL® and VAXIGRIP®:**
- The footnote explaining recommended dosing for previously unimmunized children <9 years of age has been updated to clarify that this consideration of previous vaccine receipt applies only to TIV and not to the monovalent pH1N1 vaccine (i.e., children <9 years who have not previously received TIV should be given two doses of TIV, regardless of prior receipt of pH1N1 vaccine).
- Information that was specific to the 2009-10 FLUVIRAL concerning immunogenicity findings has been removed.

**Pages 34a, 34b, and 34c - AGRIFUL®; FLUMIST®; INTANZA®:**
- Although these products will not be offered through the publicly funded 2010-11 immunization campaign, they may be available for private purchase. Separate placeholders have been added for these products pending a NACI statement regarding recommended uses and contraindications.
Please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

Table of Contents Dated July 2010
Pages 30a and 30b Dated April 2010
Page 30c Dated June 2010
Page 30d Dated November 27, 2009
Page 31 Dated October 22, 2009
Pages 32, 33, and 34 Dated October 2009

Please insert the following pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

Table of Contents,
Pages 31, 32, 33, 34, 34a, 34b, & 34c Dated September 2010

Note: Please print Table of Contents, found at: [URL]

If you have any questions or concerns, please contact Dr. Danuta Skowronski, Physician Epidemiologist, Epidemiology Services, BC Centre for Disease Control at phone: 604-707-2511 or e-mail: danuta.skowronski@bccdc.ca.

Sincerely,

[Signature]

Dr. Monika Naus,
Medical Director, Immunization Program and
Associate Medical Director, Epidemiology Services
BC Centre for Disease Control
pc: Ministry of Healthy Living and Sport:

Dr. Perry Kendall  Dr. Eric Young
Provincial Health Officer  Deputy Provincial Health Officer

Dr. Bob Fisk  Craig Thompson
Medical Consultant  Director, CD Prevention – Immunization
Non-Communicable Disease

Warren O’Briain
Executive Director
Communicable Disease and Addiction Prevention